Medical NewsCancer patients receiving drugs to lower the risk of anaemia...
Published Tuesday 01 December 2009
Chemotherapy can result in insomnia
Insomnia occurs in approximately three-quarters of cancer patients who have...
Published Tuesday 01 December 2009
Osteoarthritis risk increased by high exercise levels
Men and women in middle age who exercise on a...
Published Monday 30 November 2009
Cancer genome changes increase cervical cancer relapse risk
Patients with cervical cancer are three to four times more...
Published Sunday 29 November 2009
More Medical News
Asthma
Please note- this EPG Asthma Knowledge Centre is for Doctors and other Healthcare Professionals.
Asthma is a disorder defined by its clinical, physiological, and pathological characteristics. The main physiological feature of asthma is episodic airway obstruction characterized by expiratory airflow limitation. The dominant pathological feature is airway inflammation, sometimes associated with airway structural changes. 
Pharmacologic management of asthma aims to control symptoms, prevent exacerbations and provide the best possible pulmonary function with minimal medications, side effects and risk factors.
During exacerbations, the patient will often have wheeze and reduced lung function, either reduced peak flow or an obstructive pattern on spirometry.
Two major areas of potential improvement fof asthma. Inadequate ICS use is one of the major factors that impact the failure of long-term management.1 Also, following a general trend throughout the world, a more practical, symptom-based approach to diagnosis is warranted at the primary care level.1
There is now good evidence that the clinical manifestations of asthma—symptoms, sleep disturbances, limitations of daily activity, impairment of lung function, and use of rescue medications—can be controlled with appropriate treatment.
Enter the Asthma Knowledge Centre
What’s in the Asthma Knowledge Centre?
- Home
- Definition
- Prevalence
- Burden
- Causes of Asthma
- Development & Progression of Asthma
- Pathophysiology
- The asthmatic response
- Asthmatic Inflammation
- Inflammation in the peripheral airways
- Diagnosing
- Assessment
- Spirometry
- Airway Responsiveness
- Signs and Symptoms
- Levels of asthma control
- Classification
- Education
- Risk Factors
- Non-Pharmacological
- Pharmacological - Treatment steps for achieving control
- stepwise approach
- Corticosteroids
- Alvesco
- Pharmacokinetics
- Pharmacodynamics
- Clinical efficacy
- Safety
- Summary of Product Characteristics (SPC)
- Monitoring
- Resources
-
BECODISKS - 53.3%
... Moderate asthma (PEF values 60-80% predicted at baseline with 20-30% variability): Patients requiring regular asthma medication and patients with unstable or worsening asthma on other prophylactic therapy or bronchodilator alone. Severe asthma (PEF values less than 60% predicted at baseline with ... -
FLIXOTIDE Diskhaler - 52.72%
... intermittent symptomatic bronchodilator asthma medication on a regular daily basis. Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone. Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic ... -
SINGULAIR - 51.11%
... indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting ?-agonists provide inadequate clinical control of asthma. In those asthmatic patients in ... -
VENTODISKS - 50.03%
... adrenoceptors of bronchial muscle. With its fast onset of action, it is particularly suitable for the relief of acute asthma symptoms and the prevention of exercise induced asthma. Salbutamol provides short-acting (4-6 hour) bronchodilation with fast onset (within 5 minutes) in reversible airways ... -
PULVINAL SALBUTAMOL - 49.42%
... for the relief of symptoms of asthma, bronchospasm and/or reversible airways obstruction and for the prevention of exercise-and allergen-induced asthma. Pulvinal Salbutamol is particularly suitable for the relief of symptoms in mild, moderate and severe asthma . The use of an inhaled 2-agonist must ... -
BECLOFORTE - 49.35%
... asthma . It provides effective anti-inflammatory action in the lungs with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. Becloforte Inhaler is indicated in the prophylactic management of severe asthma in adults. Severe asthma ...